Wild Type Or Hereditary Transthyretin Amyloid Cardiomyopathy Therapeutics
1. Vyndaqel patent expiration
Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8168663 | FOLDRX PHARMS | Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof |
Dec, 2023
(2 years ago) | |
| US7214695 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2026
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8653119 | FOLDRX PHARMS | Methods for treating transthyretin amyloid diseases |
Dec, 2023
(2 years ago) | |
| US7214696 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2026
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 03, 2024 |
| Orphan Drug Exclusivity(ODE-237) | May 03, 2026 |
Drugs and Companies using TAFAMIDIS MEGLUMINE ingredient
NCE-1 date: 04 May, 2023
Market Authorisation Date: 03 May, 2019
Dosage: CAPSULE
More Information on Dosage
VYNDAQEL family patents
